市场调查报告书
商品编码
1542516
全球生物製剂合约製造市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测Global Biologics Contract Manufacturing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
全球生物製剂合约製造市场需求预计将从 2023 年的 167.7 亿美元增至 2032 年近 479.2 亿美元,2024-2032 年研究期间复合年增长率为 11.07%。
生物製品合约製造是指将生物製药产品的生产和製造过程外包给专门的合约製造组织(CMO)。生物製剂是源自活生物体的复杂治疗产品,例如蛋白质、抗体、疫苗和基于细胞的疗法。它允许製药公司、生物技术公司和学术机构利用 CMO 的专业知识、能力和基础设施,以高效且经济高效的方式大规模生产生物製剂。
在其功效和个人化医疗方法的推动下,对生物药物的需求不断增长,推动了对高效製造能力的需求。将生物製剂生产外包给专门的合约製造组织 (CMO) 可以为製药公司提供成本效率和灵活性,使他们能够专注于核心竞争力并根据需求调整产量。 CMO 满足製造过程中严格的监管标准和品质保证,确保符合法规并维持产品的安全性和有效性。生物加工领域的技术进步进一步提高了生物製品製造的效率和生产力,製药公司和 CMO 之间的合作伙伴关係推动了创新和简化流程。生物製药行业的全球市场扩张以及对生物製剂的日益重视,增强了对可靠和可扩展解决方案的需求。
研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外,这些工具还对全球生物製品合约製造市场的每个细分市场进行了包容性评估。生物製品合约製造业的成长和趋势为本研究提供了整体方法。
生物製剂合约製造市场报告的这一部分提供了国家和区域层面细分市场的详细资料,从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。
本节涵盖区域前景,重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲生物製剂合约製造市场当前和未来的需求。此外,该报告重点关注所有主要地区各个应用领域的需求、估计和预测。
该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。生物製剂合约製造市场的主要参与者包括药明生物;阿布泽纳有限公司;富士软片 Diosynth 生技公司; BI BioXcellence;龙沙集团股份公司;勃林格殷格翰有限公司;三星生物製剂;艾伯维;康泰伦特;生物依赖性; Eurofins CDMO;赛默飞世尔 (Patheon)。本节包含竞争格局的整体视图,包括各种策略发展,例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。
如果您有任何客製化要求,请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。
The global demand for Biologics Contract Manufacturing Market is presumed to reach the market size of nearly USD 47.92 Billion by 2032 from USD 16.77 Billion in 2023 with a CAGR of 11.07% under the study period 2024 - 2032.
Biologics contract manufacturing refers to the outsourcing of the production and manufacturing processes of biopharmaceutical products to specialized contract manufacturing organizations (CMOs). Biologics are complex therapeutic products derived from living organisms, such as proteins, antibodies, vaccines, and cell-based therapies. It allows pharmaceutical companies, biotechnology firms, and academic institutions to leverage the expertise, capabilities, and infrastructure of CMOs to efficiently and cost-effectively produce biologics on a large scale.
The increasing demand for biological drugs, driven by their efficacy and personalized medicine approaches, fuels the need for efficient manufacturing capabilities. Outsourcing biologics production to specialized contract manufacturing organizations (CMOs) offers cost efficiency and flexibility for pharmaceutical companies, allowing them to focus on core competencies and adjust production volumes based on demand. The stringent regulatory standards and quality assurance in this manufacturing are met by CMOs, ensuring compliance with regulations and maintaining product safety and efficacy. Technological advancements in bioprocessing further enhance the efficiency and productivity of biologics manufacturing, and collaborative partnerships between pharmaceutical companies and CMOs drive innovation and streamline processes. The global market expansion of the biopharmaceutical industry, along with the growing emphasis on biologics, reinforces the need for reliable and scalable solutions.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of biologics contract manufacturing. The growth and trends of biologics contract manufacturing industry provide a holistic approach to this study.
This section of the biologics contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Biologics Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the biologics contract manufacturing market include Wuxi Biologics; Abzena Ltd.; FUJIFILM Diosynth Biotechnologies; BI BioXcellence; Lonza Group AG; Boehringer Ingelheim GmbH; Samsung Biologics; Abbvie; Catalent; Bioreliance; Eurofins CDMO; Thermo Fischer (Patheon). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.